Cargando…
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study
BACKGROUND: Patients with hypertension and cardiovascular disease (CVD), diabetes, or chronic kidney disease (CKD) usually require two or more antihypertensive agents to achieve blood pressure (BP) goals. METHODS: The efficacy/safety of olmesartan (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hyd...
Autores principales: | Kereiakes, Dean J, Chrysant, Steven G, Izzo, Joseph L, Littlejohn, Thomas, Melino, Michael, Lee, James, Fernandez, Victor, Heyrman, Reinilde |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547771/ https://www.ncbi.nlm.nih.gov/pubmed/23110471 http://dx.doi.org/10.1186/1475-2840-11-134 |
Ejemplares similares
-
Olmesartan/Amlodipine/Hydrochlorothiazide in Obese Participants With Hypertension: A TRINITY Subanalysis
por: Roth, Eli M., et al.
Publicado: (2013) -
Combined Olmesartan, Amlodipine, and Hydrochlorothiazide Therapy in Randomized Patients with Hypertension: A Subgroup Analysis of the TRINITY Study by Age
por: Lewin, Andrew J., et al.
Publicado: (2013) -
Long-term efficacy of a combination of amlodipine and olmesartan medoxomil±hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial
por: Oparil, S, et al.
Publicado: (2010) -
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension
por: Chrysant, S G, et al.
Publicado: (2010) -
The TRINITY Study: distribution of systolic blood pressure reductions
por: Sugimoto, Danny H, et al.
Publicado: (2013)